Table 2.
Subtypes of haematological and patients with solid tumour presenting to the emergency department with sepsis
Oncology patients (N=442) | |||
Total haematological tumours, n (%) | Underwent BMT, n (%) | 28 (6.3) | |
Leukaemia, n (%) | Total | 80 (18.1) | |
ALL, n (%) | 23 (5.2) | ||
AML, n (%) | 36 (8.1) | ||
CML, n (%) | 1 (0.2) | ||
CLL, n (%) | 18 (4.1) | ||
Hairy cell leukaemia, n (%) | 2 (0.5) | ||
Lymphoma, n (%) | Hodgkin’s, n (%) | 10 (2.3) | |
Non-Hodgkin’s, n (%) | 29 (6.6) | ||
Multiple myeloma, n (%) | 11 (2.5) | ||
Myelodysplasia, n (%) | 7 (1.6) | ||
Total solid tumours, n (%) | Lung, n (%) | 69 (15.6) | |
Thyroid, n (%) | 6 (1.4) | ||
Ovarian, n (%) | 10 (2.3) | ||
Breast, n (%) | 42 (9.5) | ||
Prostate, n (%) | 29 (6.6) | ||
Liver, n (%) | 8 (1.8) | ||
Gastric, n (%) | 15 (3.4) | ||
Cervical, n (%) | 2 (0.5) | ||
Bladder, n (%) | 16 (3.6) | ||
Colorectal, n (%) | 30 (6.8) | ||
Kidney, n (%) | 8 (1.8) | ||
Gallbladder, n (%) | 13 (2.9) | ||
Pancreatic, n (%) | 36 (8.1) | ||
Other, n (%) | 21 (4.75) |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BMT, bone marrow transplant; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia.